In a 68-year-old man with tachy‑brady syndrome, bradycardia, hypertension, and chest pain, is hydralazine a dihydropyridine calcium‑channel blocker?

No, hydralazine is NOT a dihydropyridine calcium channel blocker

Hydralazine is a direct-acting vasodilator, not a calcium channel blocker of any class. This is a critical distinction with important clinical implications for your 68-year-old patient with tachy-brady syndrome, bradycardia, hypertension, and chest pain.

Mechanism of Action

Hydralazine works by directly relaxing arterial smooth muscle through mechanisms independent of calcium channel blockade 11. In contrast, dihydropyridine calcium channel blockers (such as nifedipine, amlodipine, or nicardipine) work by blocking L-type calcium channels in vascular smooth muscle 2.

Critical Clinical Implications for Your Patient

In a patient with tachy-brady syndrome and bradycardia, hydralazine may actually be preferable to calcium channel blockers because:

• Hydralazine causes reflex tachycardia through myocardial stimulation 11, which paradoxically may be less problematic than the negative chronotropic effects of non-dihydropyridine calcium channel blockers (verapamil, diltiazem)

• Dihydropyridine calcium channel blockers cause either no heart rate change or moderate transient increases 2, but non-dihydropyridines can worsen bradycardia

• Your patient's chest pain is a major concern: Hydralazine's myocardial stimulation can provoke anginal attacks and ECG changes of myocardial ischemia, and has been implicated in myocardial infarction 11. This makes hydralazine particularly dangerous in patients with suspected coronary artery disease.

Guideline-Based Positioning

According to current guidelines, hydralazine is positioned as:

• A second-line or later option for resistant hypertension after spironolactone, beta-blockers, and alpha-blockers 3
• A second-line agent for hypertensive emergencies (after IV labetalol or oral nifedipine/methyldopa) 3
• Not a first-line agent due to unpredictability of response and prolonged duration of action 4

Specific Recommendation for Your Patient

Avoid hydralazine in this patient given the combination of:

1. Chest pain (risk of myocardial ischemia/infarction)
2. Bradycardia (though reflex tachycardia might theoretically help, the unpredictable response is problematic)
3. Tachy-brady syndrome (requires careful rate control, not unpredictable reflex responses)

Consider instead: A dihydropyridine calcium channel blocker (like amlodipine) which provides predictable blood pressure lowering without negative chronotropic effects, or address the underlying tachy-brady syndrome with pacemaker placement before optimizing antihypertensive therapy 56.